COMP <GO>

COCP vs QNRX // 10Y YIELD & FRED MACRO BETA

Cocrystal Pharma Inc. (NASDAQ) VS. Quoin Pharmaceuticals Ltd. (NASDAQ) • 15-METRIC TALLY: COCP 3 — QNRX 0

■ METRIC PARITY

LAST: $1.06 (+6.53%) • MKT CAP: $20.4M

macro-sensitivity

—

LAST: $4.02 (-11.45%) • MKT CAP: $19.3M

macro-sensitivity

—

15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (COCP VS. QNRX) EMERALD CELL = QUANTITATIVE EDGE

INSTITUTIONAL METRIC	COCP	QNRX	SPREAD (A - B)	ADVANTAGE	DEDICATED URL
Gross Profit Margin	—	—	—	TIE	/gross-margins <GO>
Return on Invested Capital (ROIC)	-35.00%	-35.00%	0.00	TIE	/roic <GO>
EV/EBITDA & P/E Valuation	—	—	—	TIE	/valuation <GO>
Free Cash Flow Yield	—	—	—	TIE	/fcf-yield <GO>
Operating Margin	—	—	—	TIE	/operating-margins <GO>
Net Profit Margin	—	—	—	TIE	/net-margins <GO>
Revenue Growth (YoY)	—	—	—	TIE	/revenue-growth <GO>
Dividend Yield & FCF Payout Safety	0.00%	0.00%	0.00	TIE	/dividend-safety <GO>
Altman Z-Score & Debt/Equity	—	—	—	TIE	/balance-sheet <GO>
Piotroski F-Score Quality	3/9	2/9	+1.00	COCP	/piotroski-score <GO>
Options Implied Move & Put/Call Skew	—	—	—	TIE	/options-implied-move <GO>
RSI-14 & 200D SMA Momentum	55.1	40.6	+14.50	COCP	/rsi-technicals <GO>
10Y Yield & FRED Macro Beta ACTIVE	—	—	—	TIE	/macro-sensitivity <GO>
Forward P/E Multiple	—	—	—	TIE	/forward-pe <GO>
Enterprise Scale & Market Cap	$20.4M	$19.3M	$1.1M	COCP	/market-cap <GO>

5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY

FISCAL YEAR	COCP REV	QNRX REV	COCP GROSS %	QNRX GROSS %	COCP FCF	QNRX FCF
FY 2025	$25.3M	$8.6M	—	—	-$8.2M	-$13.5M
FY 2024	$50.1M	$6.6M	—	—	-$16.5M	-$7.9M
FY 2023	$52.0M	$39.1M	—	—	-$14.7M	-$7.9M

FRED MACRO REGIME CORRELATION COMPARISON PEARSON r

COCP // BETA —

QNRX // BETA —